Novartis has started the construction of a pharmaceutical manufacturing facility in St Petersburg, Russia.
The facility, due for completion in 2014, is expected to expand the company’s production capabilities and is Novartis’ most significant investment in Russia to date.
Built in the Novoorlovskaya Special Economic Zone, the plant will have the capacity to produce 1.5bn units a year, and will employ in more than 350 staff.
The construction is part of a $500m, five-year investment into Russian healthcare infrastructure and will address local manufacturing, R&D collaborations and public health development in the country.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData